ConductScience.org, home

Paper2017234

Biotechnology--the enormous cost of success.

Doolittle RF. N Engl J Med, 1991. Cited by 33 papers, by iCite.

Cite this record

ConductScience Library. Biotechnology--the enormous cost of success. Papers, record 2017234. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2017234

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biotechnology--the enormous cost of success.
PubMed
Journal
N Engl J Med
PubMed
Year
1991
PubMed
Publication types
Comment, Editorial
PubMed
Citations, by iCite
33
iCite
Relative citation ratio, by iCite
1.31
iCite
Revised in PubMed
2004-11-17
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Doolittle RFR F

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ErythropoietinMajor topic
Recombinant ProteinsMajor topic
Anemia
Biotechnology
Humans
Kidney Failure, Chronic
United States

Source PubMed

Download CSV of topics

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in1891031Biotechnology--the enormous cost of success.https://conductscience.org/library/papers/1891031PubMed
Comment on2017231Erythropoietin.https://conductscience.org/library/papers/2017231PubMed

Download CSV of comments and corrections

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.

PMIDTitleJournalYearIn PapersSource
10146920Drug utilisation review and pharmacoeconomics: interaction after parallel development?Pharmacoeconomics1993https://conductscience.org/library/papers/10146920PubMed
8528745Clinical trials: specific problems associated with the use of a placebo-control group.J Mol Med (Berl)1995https://conductscience.org/library/papers/8528745PubMed
8490584Quality of life. 1. Perspectives.Pharm World Sci1993https://conductscience.org/library/papers/8490584PubMed
1805823Developing new drugs for cancer.BMJ1991https://conductscience.org/library/papers/1805823PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2017234

GET https://conductscience.org/api/papers/v1/2017234/authors